Table 1

Comparison of outcomes between the Ross operation, mechAVR and biological AVR: results from the meta-analysis

	Cohorts	Ross	mechAVR	biological AVR	P value
Early mortality (%)	46	0.24 (0.17 to 0.34)	0.3 (0.19 to 0.45)	0.28 (0.16 to 0.48)	0.75
Total mortality (%/year)	47	0.54 (0.45 to 0.64)	1.38 (1.11 to 1.74)	2.54 (1.8 to 3.59)	<0.001
AoV reoperation (%/year)	47	0.54 (0.42 to 0.69)	0.37 (0.27 to 0.5)	1.28 (0.88 to 1.85)	<0.001
Bleeding (%/year)	44	0.11 (0.06 to 0.20)	0.69 (0.5 to 0.96)	0.31 (0.14 to 0.69)	<0.001
Thromboembolic events (%/year)	44	0.26 (0.19 to 0.37)	0.86 (0.62 to 1.18)	0.57 (0.39 to 0.84)	<0.001
AoV reoperations for IE (%/year)	44	0.16 (0.12 to 0.2)	0.17 (0.1 to 0.27)	0.26 (0.18 to 0.39)	0.08
Conservatively treated IE (%/year)	46	0.21 (0.15 to 0.3)	0.27 (0.18 to 0.42)	0.29 (0.1 to 0.87)	0.64
Total IE (%/year)	39	0.34 (0.27 to 0.42)	0.44 (0.3 to 0.64)	0.63 (0.32 to 1.22)	0.14
RVOT reinterventions (%/year)	22	0.43 (0.34 to 0.54)

Data are from random-effects models. Values in brackets are 95% CI.
AoV, aortic valve;IE, infective endocarditis;RVOT, right ventricular outflow tract; biological AVR, tissue aortic valve replacement;mechAVR, mechanical aortic valve replacement.